A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects

NCT02198651 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

149

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis
Musculoskeletal and Connective Tissue Diseases

Interventions

BIOLOGICAL: Adalimumab
OTHER: Placebo

Sponsor

AbbVie